BioSpace News Archive

The ALS Association announced that California’s legislature, in conjunction with the Department of Health has approved $15 million over the next five years for the wraparound model of care and treatment of ALS in the state.

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its Board of Directors has appointed Piers Morgan as a new, independent, non-executive member following a comprehensive search and selection process.

The American Urological Association is pleased to announce Raj Manocha has joined the organization as Vice President and Chief Technology Officer, reporting directly to Chief Executive Officer, Michael T. Sheppard, CPA, CAE.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021.

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced that over 20,000 spine procedures have been performed utilizing the ExcelsiusGPS® Robotic Navigation system.

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom Partner Web APIs, enabling invited third-party developers to integrate real-time CGM data into their digital health apps and devices.

LeMaitre Vascular, Inc. announced that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close.

Nortech Systems Incorporated (Nasdaq: NSYS), announced today it will release its fiscal 2021 second quarter financial results for the period ended June 30, 2021 before the markets open on Thursday, August 12.

The liquid biopsy market was valued at US$ 3,861.49 million in 2019and is projected to reach US$ 8,123.85 million by 2027; it is expected to grow at a CAGR of 9.9% during 2020–2027.